PubMed Health⌕ Search

Biomedical subjects

M Block

Publications and source records attributed to M Block.

At least 37 records · Page 2Linked to original sources
PubMed1994

A prospective randomized cross-over comparison of mono- and biphasic defibrillation using nonthoracotomy lead configurations in humans.

INTRODUCTION: For current implantable defibrillators, the nonthoracotomy approach to implantation fails in a substantial number of patients. In a prospective randomized cross-over study the defibrillation efficacy of a standard monophasic and a new biphasic waveform was compared for different lead configurations. METHODS AND RESULTS: Intraoperatively, in 79 patients receiving nonthoracotomy defibrillation leads, the defibrillation threshold was determined in the initial lead configuration for the mono- and biphasic waveform. In each patient, both waveforms were used alternately with declining energies (20, 15, 10, 5 J) until failure of defibrillation occurred. Three different initial lead configurations were tested in different, consecutive, nonrandomized patients using a bipolar endocardial defibrillation lead alone (A; n = 36) or in combination with a subcutaneous defibrillation patch (B; n = 24) or array (C; n = 19) lead. The lowest successful defibrillation energy with the biphasic waveform was less than, equal to, or higher than with the monophasic waveform in 64%, 28%, and 8% of patients, respectively, and on average significantly lower with the biphasic waveform for all three lead configurations (A: 11.3 +/- 4.4 J vs 14.5 +/- 4.5 J; B: 9.7 +/- 4.7 J vs 15.1 +/- 4.5 J; C: 7.9 +/- 4.5 J vs 12.4 +/- 4.9 J). Defibrillation efficacy at 20 J was significantly improved by the biphasic waveform (91% vs 76%). CONCLUSION: In combination with nonthoracotomy defibrillation leads, the biphasic waveform of a new implantable cardioverter defibrillator showed superior defibrillation efficacy in comparison to the standard monophasic waveform. Defibrillation thresholds were improved for lead systems with and without a subcutaneous patch or array lead.

Adult↗
PubMed1994

Dynamics of mitral regurgitant flow and orifice area. Physiologic application of the proximal flow convergence method: clinical data and experimental testing.

BACKGROUND: The proximal flow convergence method, a quantitative color Doppler flow technique, has been validated recently for calculating regurgitant flow and orifice area. We investigated the potential of the method as a tool to study different pathophysiological mechanisms of mitral valve incompetence by assessing the time course of regurgitant flow and orifice area and analyzed the implications for quantification of mitral regurgitation. METHODS AND RESULTS: Fifty-six consecutive patients with mitral regurgitation of different etiologies were studied. The instantaneous regurgitant flow rate Q(t) was computed from color M-mode recordings of the proximal flow convergence region and divided by the corresponding orifice velocity V(t) to obtain the instantaneous orifice area A(t). Regurgitant stroke volume (RSV) was obtained by integrating Q(t). Mean regurgitant flow rate Qm was calculated by RSV divided by regurgitation time. Peak-to-mean regurgitant flow rates Qp/Qm and orifice areas Ap/Am were calculated to assess the phasic character of Q(t) and A(t). In the first 24 patients (group 1), computation of Qm and RSV from the color Doppler recordings was compared with the conventional pulsed Doppler method (r = .94, SEE = 29.4 mL/s and r = .95, SEE = 9.7 mL) as well as with angiography (rs = .93 and rs = .94, P < .001). The temporal variation of Q(t) and A(t) was studied in the next 32 patients (group 2): In functional regurgitation in dilated cardiomyopathy (n = 12), there was a constant decrease in A(t) throughout systole with an increase during left ventricular relaxation; Ap/Am was 5.49 +/- 3.17. In mitral valve prolapse (n = 6), A(t) was small in early systole, increasing substantially in midsystole, and decreasing mildly during left ventricular relaxation; Ap/Am was 2.48 +/- 0.26. In rheumatic mitral regurgitation (n = 14), a roughly constant regurgitant orifice area during most of systole was found in 4 patients. In the other patients there was significant variation of A (t) and the time of its maximum; Ap/Am was 1.81 +/- 0.56. ANOVA demonstrated that the differences in Ap/Am were related to the etiology of mitral regurgitation (P < .0001). To verify that the calculated variation in regurgitant orifice area during the cardiac cycle reflects an actual variation, the ability of the method to predict a constant orifice area throughout systole was tested experimentally in a canine model of mitral regurgitation. Five flow stages were produced by implanting fixed grommet orifices of different sizes into the anterior mitral leaflet. A constant regurgitant orifice area was correctly predicted throughout systole with a mean percent error of -1.8 +/- 4% (from -6.9% to +5.8%); the standard deviation of the individual curves calculated at 10% intervals during systole averaged 13.3% (from 3.6% to 19.6%). In addition, functional mitral regurgitation caused by ventricular dysfunction was produced pharmacologically in five dogs, and the color M-mode recordings of the proximal flow convergence region were obtained with the transducer placed directly on the heart instead of the chest, thus ruling out a significant effect of translational motion on the observed flow pattern. The pattern of regurgitant flow variation was identical to that observed in patients. CONCLUSIONS: The proximal flow convergence method demonstrates that regurgitant flow and orifice area vary throughout systole in distinct patterns characteristic of the underlying mechanism of mitral incompetence. Therefore, in addition to the potential of the method as a tool to quantify mitral regurgitation, it allows analysis of the pathophysiology of regurgitation in the individual patient, which may be helpful in clinical decision making. Calculating mitral regurgitant flow rate and volume from the time-varying proximal flow field (ie, without assuming a constant orifice area that would produce overestimation in individual patients) provides excellent agreement with independent te

Adult↗
PubMed1994

[Pectoral cardioverter-defibrillator implantation combined with transvenous bipolar defibrillation electrodes].

Ultimately, implantable cardioverter-defibrillators (ICD) will one day be implantable like present pacemakers. However, due to the size of the pulse generator and the low defibrillation efficacy of monophasic shocks, only a few selected patients have been implanted transvenously-pectorally. Therefore, we have prospectively investigated whether a transvenous-pectoral approach is in general feasible with a new downsized ICD capable of delivering biphasic shocks. Out of 33 patients, 76% received a bipolar transvenous defibrillation lead system. In the first 13 consecutive patients, a randomized crossover study showed that this high efficacy was above all achieved by a superior defibrillation efficacy of the biphasic waveform in comparison to the monophasic waveform (69% vs. 23%; p = 0.03). Not a single patient could be defibrillated exclusively with the monophasic waveform. In a further 15 consecutive patients, a crossover study showed that a position of the transvenous anode within the Vena anonyma instead of the Vena cava superior is, in general, not superior (87% vs. 80%; p = 0.67). Only one patient could be exclusively defibrillated with the V. anonyma position. Intraoperatively, no complications occurred and all but one patient received a pectoral implantation of the pulse generator. Postoperatively, in five patients local complications related to the ICD system were seen; two needed a surgical revision. In two patients movements of the left shoulder joint were temporarily restricted. Thus, in the majority of patients a new downsized ICD capable of biphasic shocks can be implanted transvenously-pectorally like a pacemaker.

Adult↗
PubMed1994

[Quality assurance in interventional electrophysiology (ablation, automatic defibrillators)].

The rapid development of interventional electrophysiology during the recent years has lead to an increasing number of procedures and a wide-spread use of these techniques. Interventional electrophysiology includes catheter ablation of supraventricular and ventricular tachycardias and implantation of cardioverter-defibrillators. Measures for quality assurance aim at improving the quality of training in clinical electrophysiology as well as at giving recommendations for the personnel needed. The specific recommendations for implantation of defibrillators include the qualification of the personnel and technical prerequisites as well as recommendations for accepted indications, probable indications as well as for no indications. For catheter ablation, specific recommendations have been given as well which include the technical and personnel requirements. The presently available recommendations and guidelines help that the various elements of quality assurance obtain increasing attention and are going to affect the quality of results.

Catheter Ablation↗
PubMed1994

[Transvenous subcutaneous implantation technique of the cardioverter/defibrillator].

For years the high efficacy of implantable cardioverter-defibrillators (ICD) to prevent sudden cardiac death was impaired by the substantial perioperative mortality of the therapy. With the introduction of transvenous-subcutaneous defibrillation leads, thoracotomy could be abandoned and perioperative mortality was reduced to less than 1%. Despite frequent lead complications as dislocations, conductor fractures and isolation failures, long-term efficacy in termination of ventricular tachyarrhythmias remained approximately 98% and prevention of sudden cardiac death was not impaired. All nonthoracotomy defibrillation lead systems involve an endocardial right ventricular lead usually introduced from the left cephalic vein or directly via the subclavian vein. This lead has a pace/sense tip and at least one defibrillation electrode located in the right ventricle. Additionally, a second transvenous electrode and/or a subcutaneous patch or array electrode or the pulse generator shell has to be used for defibrillation. In combination with the biphasic defibrillation waveform, virtually all patients can be defibrillated using a combination of these electrodes. In most patients defibrillation is possible with transvenous electrodes alone and there is no need for an additional subcutaneous electrode. Smaller pulse generators have already been implanted in a subpectoral position--in many patients allowing a single incision approach as used for pacemaker implantation. Ultimately, with even smaller pulse generators ICDs should be implantable like present pacemakers in local anesthesia. This overview covers the history, models, practical aspects of implantation and testing, efficacy and complications of transvenous/subcutaneous defibrillation leads. Figures show the impact of the surgical approach on the frequency of de novo ICD implantations, X-rays of nearly all current bipolar and tripolar transvenous subcutaneous ICD lead systems, transvenous-epicardial hybrid systems and various complications. Additional figures cover lead complications not visible on X-rays. Defibrillation thresholds are compared for various lead configurations. Sensing amplitudes and pacing thresholds are compared for bipolar and pseudobipolar sense/pace leads as well as for different cardiac diseases. Tables summarize the main characteristics of current transvenous and subcutaneous ICD leads and external devices for intraoperative testing of ICD leads as well as the complications of transvenous/subcutaneous leads in three multicenter studies.

Defibrillators, Implantable↗
PubMed1994

[Allograft vasculopathy in the early phase of orthotopic heart transplantation: angiography, intravascular ultrasound and functional in vivo findings].

Accelerated graft coronary atherosclerosis disease is the main reason for long-term mortality and morbidity of heart transplant recipients. The aim of this in vivo study was to evaluate coronary atherosclerotic vessel abnormalities and endothelial function using angiography, intravascular ultrasound, and intracoronary acetylcholine infusion. Fourteen patients (11 male, 3 female; mean age 49.3 years) were examined early after heart transplantation (mean interval after transplantation: 11 weeks) because of coronary artery disease (n = 8), idiopathic dilatative cardiomyopathy (n = 7), mitral valve replacement (n: 1) or left atrial filiae of a leiomyosarcoma (n = 1). Mean age of the donor hearts (female n = 8) was 29 years; 3 patients received double- and 14 patients triple-immunosuppression. All patients underwent biplane ventriculography and coronary angiography; a total of 120 coronary segments (main stem 21, left anterior descending artery 85, circumflex artery 14) was examined by intravascular ultrasound (20 MHz, 3.5 F catheters). In 13 patients, acetylcholine was infused into the proximal left anterior descending artery (0.15 microgram/min to 150.0 micrograms/min) to evaluate vasomotion within this segment. Ventriculography demonstrated regional wall abnormalities in 2 patients, angiography revealed 9 noncritical stenotic segments in 5 patients. Intravascular ultrasound detected 52 cross-sectional areas with a three-layer appearance indicating intimal thickening. Mean circumferential expansion of intimal proliferation was 192 degrees and mean intimal thickness was 0.35 mm. Only 5 segments of the sonographically pathological cross-sectional areas showed angiographic evidence of atherosclerotic lesions. After intracoronary infusion at a lower dose (0.15 and 1.5 micrograms/min) of acetylcholine, vasoconstriction was observed in 2 patients, at a dose of 15.0 and 150.0 micrograms/min in 10 patients. This response to acetylcholine did not depend on the intravascular or angiographical extent of atherosclerotic vessel abnormalities. In heart transplant recipients, coronary artery abnormalities can already be depicted at an early stage using intravascular ultrasound. The majority of patients show coronary vasoconstriction following infusion of acetylcholine at a higher dose. Further investigation is necessary to clarify whether the depicted vessel wall abnormalities can already be interpreted as newly developed graft atherosclerosis and whether abnormal vasomotion after acetylcholine is indicative of endothelial dysfunction.

Acetylcholine↗
PubMed1993

Comparison of frequency of aggravation of ventricular tachyarrhythmias after implantation of automatic defibrillators using epicardial versus nonthoracotomy lead systems.

The time of onset of 4,471 episodes of ventricular tachycardia (VT) or fibrillation (VF) in 40 of 65 patients with an implantable cardioverter-defibrillator (ICD) with endocardial defibrillation electrodes (group 1) and in 53 of 123 with epicardial defibrillation electrodes (group 2) was analyzed to examine whether the incidence of VT/VF immediately after surgery is greater than during further follow up and whether the site of lead placement exerts an influence on the occurrence of these arrhythmias. Actuarial survival rates free of VT/VF were 77, 65, and 54% at 1, 3 and 6 months, respectively, for group 1, and 84, 66 and 52%, respectively, for group 2. The probability of VT/VF was increased only during the first week after surgery; in that week, 12.8% of all patients had VT/VF, without significant differences between groups 1 and 2. Until the end of the first month, this percentage increased to 23%, whereas only 12 to 15% of patients had VT/VF during subsequent months. In 19 patients with third-generation devices capable of terminating tachycardias by overdrive pacing, 326 of 412 VT/VF episodes occurring in the first week after surgery were terminated by antitachycardia pacing, and only 86 had to be terminated by cardioversion or defibrillation. No postoperative exacerbation of inappropriate ICD therapies was observed in any group; 2 to 5% of patients per month received ICD therapies for atrial fibrillation or sinus tachycardia. Patients who received appropriate ICD therapies in the first week after surgery were at high risk of recurrence of VT/VF.(ABSTRACT TRUNCATED AT 250 WORDS)

Defibrillators, Implantable↗
PubMed1993

Clinical experience with antitachycardia pacing and improved detection algorithms in a new implantable cardioverter-defibrillator.

OBJECTIVES: This study was conducted to assess the effectiveness of antitachycardia pacing modes and detection algorithms in patients with a new third-generation implantable cardioverter-defibrillator. METHODS: Twenty-three of 42 consecutive patients had coronary artery disease, 14 had dilated cardiomyopathy, 2 had prior valve replacement and 3 had arrhythmogenic right ventricular dysplasia. The mean ejection fraction was 41 +/- 14%; there were 31 men (74%) and 11 women, with a mean age of 53 years. On the basis of preoperative and postoperative electrophysiologic studies, in 28 patients antitachycardia pacing was postoperatively programmed randomly as "burst" (66%) or autodecremental "ramp" (34%) stimulation with a first coupling interval of 81% of tachycardia cycle length and up to 8 sequences with 3 to 10 stimuli. RESULTS: During a follow-up interval of 6.3 +/- 2.2 months, 15 patients were treated by antitachycardia pacing for a median of 6 (range 1 to 59) hemodynamically stable ventricular tachycardias (175 +/- 12 beats/min). In 5 patients, 22 ventricular tachycardias (9%) were not terminated by antitachycardia pacing but by cardioversion. Seven (3%) of these episodes accelerated (> 50 ms) during antitachycardia pacing. Syncope did not occur during these episodes. In seven patients initial antitachycardia pacing in cases of supraventricular tachycardias delayed charging and redetection prevented inappropriate discharges. Additional detection algorithms were programmed only after inappropriate therapy. The sudden "onset" and "sustained rate duration" criteria were programmed in three patients and the cycle length "stability" criteria in six patients, respectively. After activation of these detection algorithms only two of the seven patients had further inappropriate device discharges. CONCLUSIONS: Thus, antitachycardia pacing by this implantable cardioverter-defibrillator effectively and appropriately terminated 91% of hemodynamically stable ventricular tachycardias. Inappropriate device discharges were prevented in some patients by antitachycardia pacing and additional detection algorithms.

Adult↗
PubMed1993

Surgical experience with defibrillator implantation using nonthoracotomy leads.

Between October 10, 1989, and June 17, 1991, 109 patients with life-threatening ventricular arrhythmias received an implantable cardioverter-defibrillator at our institution. In 50 patients, nonthoracotomy lead systems consisting of a subcutaneous chest wall patch electrode near the cardiac apex and one (Cardiac Pacemakers, Inc: Endotak C) or two (Medtronic: Transvene) transvenous electrodes were tested. The mean ejection fraction was 0.44 +/- 0.15 with a range from 0.19 to 0.81. Twenty-four patients had a history of open heart operation. In 43 patients the nonthoracotomy lead system was implanted, whereas in 7 patients epicardial patch lead systems were required due to elevated defibrillation thresholds during nonthoracotomy lead testing. There was one perioperative death unrelated to the operative procedure (hydrocephalus internus). Hemorrhage from the subcutaneous patch pocket or the device pocket that required reintervention occurred in 4 patients. During a mean follow-up of 13 +/- 5 months (range, 4 to 26 months) no dislocation of an endocardial lead, insulation defect, or lead fracture has been observed. In 1 patient, the lead system had to be removed due to infection of the subcutaneous patch pocket. The cardiovascular survival rate was 98% at 12 and 18 months, and freedom from sudden cardiac death was 100% at 6 and 12 months. In conclusion, defibrillator implantation using nonthoracotomy lead systems is feasible with a success rate of 86%, and during short-term follow-up no problems related to the lead system such as dislocation, fracture, or insulation defect have occurred.

Adolescent↗
PubMed1993

Do patients with an implantable defibrillator live longer?

OBJECTIVES: This study was done to provide information on the potential benefit of implantable cardioverter-defibrillator therapy regarding sudden and arrhythmia-related deaths and to examine whether such therapy improves survival. BACKGROUND: Implantation of automatic cardioverter-defibrillators is reported to abort sudden cardiac death due to malignant tachyarrhythmias. METHODS: Between 1989 and 1992, 107 patients were screened for implantation of a third-generation implantable cardioverter-defibrillator combined with endocardial leads. Mean age was 57 +/- 13 years and mean ejection fraction was 40 +/- 15%. Sudden death, total arrhythmia-related death and total cardiac death were compared with the occurrence of fast ventricular tachyarrhythmias (> 240 beats/min), assuming that most of these arrhythmias would have been fatal without treatment by the implantable cardioverter-defibrillator. RESULTS: The surgical mortality rate was 2.7% in all 107 patients and 1% in the 99 patients who qualified for endocardial leads. During a follow-up period of 12 +/- 8 months, actuarial survival rate free of events at 6 months as well as at 12 and 18 months was 100% for sudden death, 97% for total arrhythmia-related death and 95% for total cardiac death. In contrast, after 6, 12 and 18 months, the rate of survival free of fast ventricular tachycardia was only 83%, 74% and 69%, respectively, and the rate of survival free of any ventricular tachyarrhythmia was only 59%, 49% and 40%, respectively. CONCLUSIONS: The outcome of patients treated with an implantable cardioverter-defibrillator and endocardial defibrillation leads is excellent. For many patients, this treatment is probably lifesaving.

Adult↗
PubMed1993

Radiofrequency catheter ablation of ventricular tachycardia following implantation of an automatic cardioverter defibrillator.

OBJECTIVES: The present study reports on the complementary role of two nonpharmacological options of antiarrhythmic therapy. BACKGROUND: Catheter ablation, antitachycardia surgery, and the implantable cardioverter defibrillator (ICD) have become important tools in the management of ventricular tachyarrhythmias. However, the emergence of ventricular tachyarrhythmias after implantation of an ICD is possible because the arrhythmogenic substrate is not affected. PATIENTS AND METHODS: Six of 180 patients developed frequent episodes of monomorphic ventricular tachycardia (n = 2) or incessant ventricular tachycardia (n = 4) following implantation of an ICD and underwent radiofrequency (RF) catheter ablation. Catheter ablation was performed using a RF generator HAT 200. Energy was delivered between a 4-mm tip electrode of the ablation catheter and a patch electrode. RESULTS: Catheter ablation was done 6.8 +/- 5 months following ICD implantation; 6 +/- 2.2 RF impulses were delivered at the site of origin of ventricular tachycardia characterized by early endocardial activation during ventricular tachycardia, identical pace mapping and long latency between stimulus, and QRS-complex in five patients. New bundle branch reentry was the underlying mechanism of ventricular tachycardia in one patient. RF catheter ablation resulted in termination of incessant ventricular tachycardia. Immediately postablation, the documented ventricular tachycardia was rendered noninducible in all patients. No ICD malfunctions have been observed. One patient died due to heart failure 24 hours after successful ablation of the incessant ventricular tachycardia. During a follow-up of 5-19 months, episodes of ventricular tachycardia recurred in four patients. All episodes could be controlled by the ICD without frequent cardioversions. CONCLUSION: RF catheter ablation is a complementary therapeutic option in case of frequent or incessant ventricular tachycardia after ICD implantation.

Adult↗
PubMed1993

[Therapy of ventricular tachyarrhythmia with implantable cardioverters/defibrillators--mortality and complications using epicardial electrodes].

Technical improvements of third generation implantable cardioverter defibrillators (ICD) like antitachycardia pacing modalities lead to an extended use of ICDs, not only in patients with aborted sudden cardiac death, but also in patients with hemodynamically tolerable ventricular tachycardia. In addition, anticipated results of current prospective studies might indicate the prophylactic use of ICDs in patients with high risk for sudden cardiac death, but without documented ventricular tachyarrhythmias. This report reviews mortality and complications associated with the ICDs with epicardial defibrillation leads. Mortality is separated in cardiac death, sudden cardiac, arrhythmogenic "not so sudden" cardiac death, and overall mortality. Pulmonary complications and infections are related to the underlying disease and the surgical procedure. Device- and lead-related complications, high defibrillation thresholds, pacemaker interactions, inappropriate shocks, arrhythmic effects, syncope, and psychosocial problems are reported, respectively.

Adolescent↗
PubMed1993

[Diagnostic and therapeutic problems in idiopathic prolonged QT syndrome. A case report].

The case of a 36-year-old woman with suspected idiopathic long QT syndrome is reported. Diagnosis was made late after syncopal attacks and several episodes of resuscitation had occurred. Although therapy with a beta-blocking agent was initiated and a cardioverter/defibrillator was implanted, the patient died, due to a hydrocephalus internus resulting in cerebral damage. Diagnostic and therapeutic problems in idiopathic long QT syndrome are discussed.

Adult↗
PubMed1992

Doppler echocardiographic assessment of the pressure gradient during bicycle ergometry in hypertrophic cardiomyopathy.

To assess the behavior of the subvalvular pressure gradient under physical exercise, 13 patients with obstructive hypertrophic cardiomyopathy were examined during upright bicycle ergometry by means of Doppler echocardiography. Additionally, right-sided cardiac catheterization was performed within 7 days. In 10 patients adequate Doppler tracings could be obtained during exercise. The Doppler-derived systolic pressure gradient increased from 75 +/- 24 to 140 +/- 42 mm Hg (p less than 0.0005). This was associated with an increase in the duration of the systolic mitral-septal contact from 59 +/- 21 to 136 +/- 28 ms (p less than 0.0005). Correlation between the pressure gradient and the duration of mitral-septal contact at rest and during exercise was good (r = 0.86), whereas correlation between the resting and exercise pressure gradient (r = 0.34) did not reach statistical significance. The increase in stroke volume during exercise, from 90 +/- 18 to 95 +/- 24 ml, was significant (p less than 0.05) but minimal. Therefore, only a moderate increase in systolic flow, from 205 +/- 54 to 268 +/- 78 ml/s (p less than 0.0005), was observed. Outflow tract resistance, defined as the ratio of the pressure gradient to systolic flow, increased from 0.38 +/- 0.11 to 0.57 +/- 0.24 mm Hg.s/ml (p less than 0.01). Thus, in a selected group of patients with hypertrophic cardiomyopathy a substantial increase in the maximal pressure gradient during upright bicycle ergometry was demonstrated in most patients. Exercise Doppler echocardiography may be valuable to assess the hemodynamic significance of obstruction in individual patients in a physiologic setting and has a potential to monitor the effect of therapeutic interventions.

Adult↗